JCC: AlphaE整合素表达在克罗恩病患者回肠中增加并且不受炎症影响

2018-11-10 MedSci MedSci原创

最近的研究结果表明,αE整合素表达在效应T细胞上会明显富集,并且肠αE+T细胞具有增加的炎性细胞因子的表达。αE整合素表达是对etrolizumab反应的潜在预测生物标志物,etrolizumab是针对β4整合素的单克隆抗体,其靶向α4β7和αEβ7。研究人员在本项研究中评估了健康和炎症性肠病患者中αE+细胞的流行和定位以及总αE基因表达情况。

背景
最近的研究结果表明,αE整合素表达在效应T细胞上会明显富集,并且肠αE+T细胞具有增加的炎性细胞因子的表达。αE整合素表达是对etrolizumab反应的潜在预测生物标志物,etrolizumab是针对β4整合素的单克隆抗体,其靶向α4β7和αEβ7。研究人员在本项研究中评估了健康和炎症性肠病患者中αE+细胞的流行和定位以及总αE基因表达情况。

方法
研究人员通过免疫组织化学的方法在回肠和结肠活组织检查中鉴定αE+细胞,并使用自动算法计数。通过定量逆转录酶聚合酶链反应评估基因表达。

结果
在健康和炎症性肠病患者中,与结肠活组织检查相比,回肠的上皮和固有层中存在显着更多的αE+细胞。与结肠活组织检查相比,回肠中αE基因表达水平也显着更高。来自同一患者的成对活组织检查显示回肠和结肠之间αE表达存在相关性。炎症不影响αE表达,内窥镜检查和组织学评分均未与αE基因表达相关。

结论
在炎性肠病患者中,无论炎症状态或维持药物如何,αE水平都是稳定的,这可以支持其作为etrolizumab的生物标志物的用途。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779696, encodeId=6b361e79696c7, content=<a href='/topic/show?id=624423539a' target=_blank style='color:#2F92EE;'>#alphaE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2353, encryptionId=624423539a, topicName=alphaE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Feb 21 06:13:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008398, encodeId=c259200839893, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 21 15:13:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048243, encodeId=33b3204824315, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu May 02 18:13:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036004, encodeId=329620360041b, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Dec 26 11:13:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459465, encodeId=dfc3145946517, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511343, encodeId=fd66151134376, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779696, encodeId=6b361e79696c7, content=<a href='/topic/show?id=624423539a' target=_blank style='color:#2F92EE;'>#alphaE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2353, encryptionId=624423539a, topicName=alphaE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Feb 21 06:13:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008398, encodeId=c259200839893, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 21 15:13:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048243, encodeId=33b3204824315, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu May 02 18:13:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036004, encodeId=329620360041b, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Dec 26 11:13:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459465, encodeId=dfc3145946517, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511343, encodeId=fd66151134376, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=)]
    2019-09-21 changfy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779696, encodeId=6b361e79696c7, content=<a href='/topic/show?id=624423539a' target=_blank style='color:#2F92EE;'>#alphaE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2353, encryptionId=624423539a, topicName=alphaE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Feb 21 06:13:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008398, encodeId=c259200839893, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 21 15:13:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048243, encodeId=33b3204824315, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu May 02 18:13:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036004, encodeId=329620360041b, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Dec 26 11:13:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459465, encodeId=dfc3145946517, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511343, encodeId=fd66151134376, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=)]
    2019-05-02 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779696, encodeId=6b361e79696c7, content=<a href='/topic/show?id=624423539a' target=_blank style='color:#2F92EE;'>#alphaE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2353, encryptionId=624423539a, topicName=alphaE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Feb 21 06:13:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008398, encodeId=c259200839893, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 21 15:13:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048243, encodeId=33b3204824315, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu May 02 18:13:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036004, encodeId=329620360041b, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Dec 26 11:13:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459465, encodeId=dfc3145946517, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511343, encodeId=fd66151134376, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=)]
    2018-12-26 jiekemin
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779696, encodeId=6b361e79696c7, content=<a href='/topic/show?id=624423539a' target=_blank style='color:#2F92EE;'>#alphaE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2353, encryptionId=624423539a, topicName=alphaE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Feb 21 06:13:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008398, encodeId=c259200839893, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 21 15:13:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048243, encodeId=33b3204824315, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu May 02 18:13:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036004, encodeId=329620360041b, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Dec 26 11:13:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459465, encodeId=dfc3145946517, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511343, encodeId=fd66151134376, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1779696, encodeId=6b361e79696c7, content=<a href='/topic/show?id=624423539a' target=_blank style='color:#2F92EE;'>#alphaE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2353, encryptionId=624423539a, topicName=alphaE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Feb 21 06:13:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008398, encodeId=c259200839893, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 21 15:13:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048243, encodeId=33b3204824315, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu May 02 18:13:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036004, encodeId=329620360041b, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Dec 26 11:13:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459465, encodeId=dfc3145946517, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511343, encodeId=fd66151134376, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b1110335485, createdName=Tamikia, createdTime=Mon Nov 12 07:13:00 CST 2018, time=2018-11-12, status=1, ipAttribution=)]
    2018-11-12 Tamikia

相关资讯

JCC: 肌肉减少症是溃疡性结肠炎患者需要抢救治疗的预测因子

溃疡性结肠炎患者中有近四分之一的患者深受急性重症溃疡性结肠炎[ASUC]的影响,因此我们需要一些临床指标来预测何种患者会患有ASUC。肌肉减少症和内脏肥胖可预测克罗恩病的自然病史,但这些代谢因素对ASUC结局的作用尚不清楚。本研究的目的是确定肌肉减少症和内脏肥胖对ASUC结局的影响。

JCC :溃疡性结肠炎中内镜评分与组织学评分可以通过验证指数很好的关联起来

内镜检查和组织病理评估是评估溃疡性结肠炎疾病活动的关键;但目前尚未有研究将内镜和组织学指标进行相关性分析。本项研究的目标是将溃疡性结肠炎内窥镜严重程度指数[UCEIS]与已建立UC患者的两个新的验证组织学指标进行相关性分析。

BMC Gastroenterology: 粪便钙卫蛋白可用于评估UC内镜活动和预测中度活动度UC患者接受粒细胞分离术的疗效

钙卫蛋白是一种中性粒细胞分泌的蛋白,它可以在粪便样品中检测出来。在溃疡性结肠炎(UC)的疾病活动期间,钙卫蛋白的粪便水平会明显增加。尽管如此,目前尚未有充分的研究来阐明粪便钙卫蛋白(FC)与粒细胞分离术(GMA)治疗UC中的相关性。本项前瞻性研究旨在探究FC是否可以评估疾病活动以及预测GMA治疗的UC患者的效果。

IBD: 炎症性肠病对维多珠单抗失应答的预测因素

临床工作中有部分患者对维多珠单抗(VDZ)的会出现失应答(LOR),本项研究就这一现象进行了评估,并试图寻找影响对维多珠单抗应答的危险因素。

BMC Gastroenterology:维多珠单抗可用于治疗抗TNF-α治疗失败的炎症性肠病患者

维多珠单抗(Vedolizumab)在治疗患有克罗恩病(CD)和溃疡性结肠炎(UC)的成年患者中是很有成效的;然而,其在治疗儿童炎症性肠病(IBD)患者中的数据很少。因此,研究人员评估了维多珠单抗(vedolizumab)在奥地利IBD患儿中的疗效情况。

IBD:结肠胶囊内镜检查可以作为UC的简单有效的检查方法

随着科技的进步,第二代结肠胶囊内镜(CCE-2)越来越多的应用在监测溃疡性结肠炎(UC)中。但是,CCE-2的排泄率仍然不能令人满意,并且肠道准备方案也存在一定的缺陷。因此,本研究旨在开发一个简单的1天CCE-2检查程序,同时评估其在UC中的排泄率和可接受性。